Oral contraceptives use and development of obesity in a Mediterranean cohort: the SUN (Seguimiento Universidad de Navarra) Project.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
23
01
2019
accepted:
15
07
2019
revised:
01
07
2019
pubmed:
31
8
2019
medline:
27
2
2021
entrez:
31
8
2019
Statut:
ppublish
Résumé
The use of oral contraceptives (OC) has been suggested to represent a potential risk factor for the development of obesity. However, the available literature assessing the relationship between OC use and the development of obesity is still scarce and characterised by controversial heterogeneity. We prospectively evaluated the association between the use of OC and the development of obesity in female participants of a middle-aged and free-living cohort. The study population included 4920 female Spanish university graduates, initially nonobese women, with mean age (standard deviation) 28.2 (5.4) years. The study population was followed up for a mean of 8.6 (3.7) years. Self-reported use of OC and body mass index were assessed at baseline and biennially during follow-up. We used generalized estimating equation models to evaluate the association between exposure to OC and the development of obesity. After adjusting for potential confounders, baseline OC use was associated with higher odds of new-onset obesity during the full follow-up period (multivariable-adjusted odds ratio [OR] = 1.78; 95% Confidence Interval [CI]: 1.01-3.15). The continued use of OC for periods of time longer than 2 years was significantly associated with a higher risk of developing obesity (OR = 2.82, 95% CI: 1.17-6.82). According to our prospective cohort study, OC use is significantly associated with higher odds of obesity development, especially when the use of OC is steady and extends over periods of more than 2 years.
Sections du résumé
BACKGROUND
The use of oral contraceptives (OC) has been suggested to represent a potential risk factor for the development of obesity. However, the available literature assessing the relationship between OC use and the development of obesity is still scarce and characterised by controversial heterogeneity. We prospectively evaluated the association between the use of OC and the development of obesity in female participants of a middle-aged and free-living cohort.
METHODS
The study population included 4920 female Spanish university graduates, initially nonobese women, with mean age (standard deviation) 28.2 (5.4) years. The study population was followed up for a mean of 8.6 (3.7) years. Self-reported use of OC and body mass index were assessed at baseline and biennially during follow-up. We used generalized estimating equation models to evaluate the association between exposure to OC and the development of obesity.
RESULTS
After adjusting for potential confounders, baseline OC use was associated with higher odds of new-onset obesity during the full follow-up period (multivariable-adjusted odds ratio [OR] = 1.78; 95% Confidence Interval [CI]: 1.01-3.15). The continued use of OC for periods of time longer than 2 years was significantly associated with a higher risk of developing obesity (OR = 2.82, 95% CI: 1.17-6.82).
CONCLUSIONS
According to our prospective cohort study, OC use is significantly associated with higher odds of obesity development, especially when the use of OC is steady and extends over periods of more than 2 years.
Identifiants
pubmed: 31467420
doi: 10.1038/s41366-019-0442-9
pii: 10.1038/s41366-019-0442-9
doi:
Substances chimiques
Contraceptives, Oral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
320-329Références
World Health Organization. Obesity and overweight fact sheet. Geneva: WHO; 2018.
Instituto Nacional de Estadística. Encuesta Europea de Salud en España, 2017. Madrid: Instituto Nacional de Estadística; 2017.
González-Muniesa P, Mártinez-González MA, Hu FB, Després JP, Matsuzawa Y, Loos RJF, et al. Obesity. Nat Rev Dis Primers. 2017;3:17034.
doi: 10.1038/nrdp.2017.34
World Health Organization. Global status report on noncommunicable diseases. Geneva: WHO; 2014.
GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.
doi: 10.1056/NEJMoa1614362
Nelson AL. Combined oral contraceptives. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, editors. Contraceptive technology, 19th ed. New York: Ardent Media; 2008:193–270.
Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–82.
doi: 10.1016/S0002-9378(98)70047-X
United Nations. World contraceptive patterns, 2015. New York: United Nations Publications; 2015.
Amado JA, Flórez J. Hormonas sexuales: estrógenos, gestágenos, andrógenos y anticonceptivos hormonales. In: Flórez J, Armijo JA, Mediavilla A, editors. Farmacología humana. 6th ed. Barcelona, Spain: Elsevier-Masson; 2013. p. 867–90.
Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1:CD003987.
Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016;8:CD008815.
Carlos S, De La Fuente-Arrillaga C, Bes-Rastrollo M, Razquin C, Rico-Campà A, Martínez-González MA, et al. Mediterranean diet and health outcomes in the SUN cohort. Nutrients. 2018;10:349.
doi: 10.3390/nu10040439
Bes-Rastrollo M, Pérez Valdivieso J, Sánchez-Villegas A, Alonso A, Martínez-González MA. Validación del peso e índice de masa corporal auto-declarados de los participantes de una cohorte de graduados universitarios. Rev Esp Obes. 2005;3:352–8.
Martín-Moreno JM, Boyle P, Gorgojo L, Maisonneuve P, Fernández-Rodríguez JC, Salvini S, et al. Development and validation of a food frequency questionnaire in Spain. Int J Epidemiol. 1993;22:512–9.
doi: 10.1093/ije/22.3.512
Fernández-Ballart JD, Piñol JL, Zazpe I, Corella D, Carrasco P, Toledo E, et al. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr. 2010 103:1808–16.
doi: 10.1017/S0007114509993837
De la Fuente-Arrillaga C, Ruiz ZV, Bes-Rastrollo M, Sampson L, Martinez-González MA. Reproducibility of an FFQ validated in Spain. Public Health Nutr. 2010;13:1364–72.
doi: 10.1017/S1368980009993065
Martinez-Gonzalez MA, Lopez-Fontana C, Varo JJ, Sanchez-Villegas A, Martinez JA. Validation of the Spanish version of the physical activity questionnaire used in the Nurses’ Health Study and the Health Professionals’ Follow-up Study. Public Health Nutr. 2005;8:920–7.
doi: 10.1079/PHN2005745
Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, et al. 2011 Compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43:1575–81.
doi: 10.1249/MSS.0b013e31821ece12
Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol. 2001;153:865–74.
doi: 10.1093/aje/153.9.865
Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, Westhoff C, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016;8:CD008452.
Simmons KB, Edelman AB. Hormonal contraception and obesity. Fertility and Sterility. 2016;106:1282–8.
doi: 10.1016/j.fertnstert.2016.07.1094
Lindh I, Ellström AA, Milsom I. The long-term influence of combined oral contraceptives on body weight. Hum Reprod. 2011;26:1917–24.
doi: 10.1093/humrep/der094
Oelkers W. Drospirenone—a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care. 2000;5(Suppl 3):17–24.
pubmed: 11246598
Casals-Casas C, Desvergne B. Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol. 2011;73:135–62.
doi: 10.1146/annurev-physiol-012110-142200
Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol. 2013;42:1012–4.
doi: 10.1093/ije/dys223